Myasthenia Clinical Trials

106 recruitingLast updated: July 25, 2026

There are 106 actively recruiting myasthenia clinical trials across 36 countries. Studies span Phase 3, Phase 2, Phase 1, Not Applicable, Phase 4, Early Phase 1. Top locations include Warsaw, Poland, Tampa, Florida, United States, Boca Raton, Florida, United States. Updated daily from ClinicalTrials.gov.


Myasthenia Trials at a Glance

106 actively recruiting trials for myasthenia are listed on ClinicalTrialsFinder across 6 cities in 36 countries. The largest study group is Phase 3 with 22 trials, with the heaviest enrollment activity in Warsaw, Tampa, and Boca Raton. Lead sponsors running myasthenia studies include argenx, Centre Hospitalier Universitaire de Nice, and Alexion Pharmaceuticals, Inc..

Browse myasthenia trials by phase

Treatments under study

About Myasthenia Clinical Trials

Looking for clinical trials for Myasthenia? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myasthenia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myasthenia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 106 trials

Recruiting
Phase 2

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

Myasthenia Gravis (MG)gMGAChR-Ab Seropositive Generalized Myasthenia Gravis+1 more
argenx40 enrolled2 locationsNCT07673627
Recruiting
Phase 3

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany264 enrolled145 locationsNCT06463587
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Myasthenia GravisMultiple Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company120 enrolled35 locationsNCT06220201
Recruiting
Phase 2

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized
Vertex Pharmaceuticals Incorporated30 enrolled24 locationsNCT07501702
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

Myasthenia Gravis
TG Therapeutics, Inc.120 enrolled2 locationsNCT07673744
Recruiting

PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis

Myasthenia Gravis, Generalized
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico40 enrolled1 locationNCT07717281
Recruiting

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Rare DiseasesGeneralized Myasthenia Gravis (gMG)
AstraZeneca450 enrolled7 locationsNCT07247279
Recruiting
Phase 2

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

Generalized Myasthenia Gravis
Amgen15 enrolled4 locationsNCT06987539
Recruiting
Phase 3

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

Myasthenia Gravis, Generalized
Dianthus Therapeutics195 enrolled1 locationNCT07647510
Recruiting

Capturing Key MG-symptoms Using Smartphone Recordings.

FatigueMyasthenia Gravis
Leiden University Medical Center225 enrolled2 locationsNCT06743490
Recruiting
Phase 2Phase 3

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Myasthenia GravisGeneralized Myasthenia Gravis
Kyverna Therapeutics66 enrolled22 locationsNCT06193889
Recruiting
Phase 2Phase 3

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Myasthenia Gravis
Janssen Research & Development, LLC12 enrolled19 locationsNCT05265273
Recruiting
Phase 3

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

Myasthenia Gravis
Janssen Research & Development, LLC115 enrolled15 locationsNCT07217587
Recruiting
Phase 2Phase 3

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
UCB Biopharma SRL8 enrolled9 locationsNCT06055959
Recruiting
Phase 1

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled6 locationsNCT07304154
Recruiting
Phase 2

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

Myasthenia GravisMyasthenia Gravis, MuSK
NMD Pharma A/S84 enrolled40 locationsNCT06414954
Recruiting
Phase 1Phase 2

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
Novartis Pharmaceuticals15 enrolled11 locationsNCT06704269
Recruiting
Phase 3

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

Generalized Myasthenia Gravis
Novartis Pharmaceuticals146 enrolled125 locationsNCT06517758
Recruiting
Phase 2Phase 3

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Generalized Myasthenia Gravis
UCB Biopharma SRL12 enrolled14 locationsNCT06149559
Recruiting

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized
AstraZeneca50 enrolled12 locationsNCT06909253